Promising COVID-19 rapid test technology enters phase 1 of NIH challenge
Highly competitive NIH RADx program selects Rover Diagnostics and biomedical engineer Sam Sia to refine and validate their low-cost, ultrafast RT PCR testCredit: Bulent Onalir/Rover...
















